Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer.

@article{Hawkins2005SafetyAT,
  title={Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer.},
  author={Robert Edward Hawkins and Luc Daigneault and Richard Cowan and Richard Griffiths and Chandra Panchal and Anne V Armstrong and Jackie Fenemore and Alan Irvine and Kasia Sereda and H{\'e}l{\`e}ne Dulude},
  journal={Clinical prostate cancer},
  year={2005},
  volume={4 2},
  pages={91-9}
}
BACKGROUND The safety, tolerability, and pharmacokinetic and preliminary efficacy of PCK3145 were determined in patients with metastatic hormone-refractory prostate cancer. PATIENTS AND METHODS PCK3145 was administered in ascending doses of 5, 20, 40, and 80 mg/m2 3 times per week for 4 weeks to cohorts of 4 patients. Dose escalation was based on dose-limiting toxicity (DLT). Pharmacokinetic profiles, tumor burden, and tumor markers (including prostate-specific antigen [PSA] and matrix… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…